Verrica Pharmaceuticals (VRCA) Accumulated Expenses (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Accumulated Expenses of $12.3 million for Q1 2026, down 15.42% year-over-year from $14.5 million in Q1 2025, and down 4.56% quarter-over-quarter from $12.8 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Accumulated Expenses (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $12.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 15.42% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (down 15.42% YoY), while the FY2025 annual figure was $12.8 million, down 4.99% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $12.3 million, down from $12.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $18.9 million in Q3 2024, with the low at $219000.0 in Q1 2022.
- The 5-year median for Accumulated Expenses is $12.3 million (2026), against an average of $8.7 million.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 77.78% in 2022, then jumped 1290.5% in 2023.
- Verrica Pharmaceuticals' Accumulated Expenses stood at $2.7 million in 2022, then climbed by 29.49% to $3.4 million in 2023, then soared by 292.99% to $13.5 million in 2024, then declined by 4.99% to $12.8 million in 2025, then retreated by 4.56% to $12.3 million in 2026.
- Business Quant data shows VRCA's Accumulated Expenses at $12.3 million in Q1 2026, $12.8 million in Q4 2025, and $12.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.55 Mn |
| Mar 31, 2026 | 12.25 Mn |
| Dec 31, 2025 | 12.84 Mn |
| Sep 30, 2025 | 12.60 Mn |
| Jun 30, 2025 | 13.10 Mn |
| Mar 31, 2025 | 14.48 Mn |
| Dec 31, 2024 | 13.51 Mn |
| Sep 30, 2024 | 18.90 Mn |
| Jun 30, 2024 | 17.85 Mn |
| Mar 31, 2024 | 15.83 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 3.37 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 242,000.00 |
| Mar 31, 2022 | 219,000.00 |
| Dec 31, 2021 | 3.27 Mn |
| Sep 30, 2021 | 242,000.00 |